Multiple Sclerosis Resource Centre
  • Home
  • About MS
  • MSRC Services
  • Get Involved
  • MS Research News
  • MSRC Groups
  • Useful Resources
  • Welcome To Josephs Court, MS Centre Of Excellence
  • Advertising
  • Best Bet Diet Group
  • E-Newsletter
  • Contact Us
  • Investor in People
    You are here : Home » MS Research News » Neuropsychiatric and Psychological

    Neuropsychiatric and Psychological

    A A A
    [Print this page]

    Share |


    More news can be found in New Pathways Magazine , our bi-monthly publication, and also check daily at MSRC: Latest MS News.

    A large-scale study of anxiety and depression in people with MS

    Depression and MSSummary: This large, new study from the UK has used responses gained via the web portal of the UK MS Register to investigate the depression and anxiety profiles of people with MS, and to determine if anxiety and depression are linked to stage of disease or other demographic factors. In the 4178 respondents, anxiety and depression rates were extremely high, with over half of patients scoring highly on anxiety and depression clinical rating scales.

    Women with relapsing-remitting MS (RRMS) were more anxious than men with RRMS and women with other MS subtypes. Patients with secondary progressive MS suffered most from depression. The outcomes from studies of this type continue to shed light the extent of mental health problems in patients with MS and will highlight the need for better mental health care of patients.

    Abstract

    INTRODUCTION:
    Studies have found that people with Multiple Sclerosis experience relatively high rates of anxiety and depression. Although methodologically robust, many of these studies had access to only modest sample sizes (N<200). The aims of this study were to use responses gained via the web portal of the UK MS Register (N>4000) to: describe the depression and anxiety profiles of people with MS; to determine if anxiety and depression are related to age or disease duration; and to assess whether the levels of anxiety and depression differ between genders and types of MS.

    METHODS:
    From its launch in May 2011 to the end of December 2011, 7786 adults with MS enrolled to take part in the UK MS Register via the web portal. The responses to the Hospital Anxiety and Depression Scale (HADS) were collated with basic demographic and descriptive MS data provided at registration and the resulting dataset was analysed in SPSS (v.16).

    RESULTS:
    The mean HADS score among the 4178 respondents was 15.7 (SE 0.117, SD 7.55) with a median of 15.0 (IQR 11). Anxiety and depression rates were notably high, with over half (54.1%) scoring ≥8 for anxiety and 46.9% scoring ≥8 for depression. Women with relapsing-remitting MS were more anxious than men with this type (p<0.001), and than women with other types of MS (p = 0.017). Within each gender, men and women with secondary progressive MS were more depressed than men or women with other types of MS (p<0.001, p<0.001).

    CONCLUSIONS:
    This largest known study of its kind has shown that anxiety and depression are highly prevalent in people with MS, indicating that their mental health needs could be better addressed. These findings support service planning and further research to provide the best care for people with MS to help alleviate these debilitating conditions.

    Jones KH, Ford DV, Jones PA, John A, Middleton RM, Lockhart-Jones H, Osborne LA, Noble JG.

    College of Medicine, Swansea University, Swansea, Wales, United Kingdom.

    Source: PLoS One. 2012;7(7):e41910. Epub 2012 Jul 30 & Pubmed PMID: 22860028 PMCID: PMC3408498 (08/08/12)

    Multiple Sclerosis patients face cluster of mental disorders

    MS And DepressionPeople with multiple sclerosis face higher levels of anxiety, depression and fatigue than the general population and often have to battle all three simultaneously, a Tasmanian study reveals.

    More than half (53.7%) of the 198 multiple sclerosis patients in the study reported fatigue, while 44.5% experienced anxiety and 18.5% had symptoms of depression, the longitudinal study covering an estimated 78% of all multiple sclerosis patients in southern Tasmania, found.

    Levels of anxiety were about four times higher than those for the general population in South Australia and the prevalence of depression was about twice the norm, the authors wrote in Multiple Sclerosis Journal.

    “In particular, 11.7% of people had all three factors concurrently and this was 2.65 times greater than expected by chance”, the authors said.

    “The fact that they concur together made us wonder about a common mechanism,” coauthor Professor Bruce Taylor of the University of Tasmania, told Neurology Update.

    There might be a common cause, he speculated. “There’s certainly a lot of evidence that there may be an inflammatory component to depression and there may be inflammatory components to fatigue and also multiple sclerosis, so that’s why we think there may be a link between them. We are now looking at which genes are involved in predisposing people to all these conditions.”

    Depression was often considered the most common psychological disorder in people with multiple sclerosis, but their study had shown anxiety was twice as common, he continued.

    No association was found between anxiety levels and the length of time patients had had mulitple sclerosis, but older patients were less likely to be anxious.

    Depression was markedly greater in patients who scored high on the Expanded Disability Status Scale.

    Professor Taylor said that if clinicians found one of the disorders, for example depression, they needed to be aware that they often concurred and should check for anxiety and fatigue as well.

    Multiple Sclerosis Journal, 2012: doi: 10.1177/1352458512450351

    Soure: Neurology Update (26/06/12)

    Depression, cognitive impairment often complicate Multiple Sclerosis

    DepressionPatients with multiple sclerosis often also manifest major depression or cognitive impairments, but these associated conditions frequently go undiagnosed or untreated, experts said at the annual congress of the European College of Neuropsychopharmacology.

    "The data are strong now that depression is common" in patients with multiple sclerosis (MS), with a lifetime prevalence in MS patients of about 50%, said Dr. Anthony Feinstein, professor of psychiatry at the University of Toronto. "There must be something particular about MS that predisposes patients to depression.

    "You know that [many MS] patients are going to have major behavioral disturbances. The MS rating scales do not take this into account. They are very oriented to motor symptoms, and ignore to a large degree cognitive and behavioral disturbances," he said in an interview. "The behavioral disturbances can be profound."

    Cognitive impairment occurs in "up to two-thirds of MS patients, relatively independent of physical disability," said John DeLuca, Ph.D., at the same session. "Cognitive impairment can be seen in early stages [of MS], late stages, or never," said Dr. DeLuca, vice president for research at the Kessler Foundation in West Orange, N.J.

    Diagnosing and treating depression in MS patients is important as it can affect quality of life and cognition, and can result in suicidality, said Dr. Feinstein. Suicide among MS patients runs more than sevenfold higher than in the general population, and twice as high compared with patients with other types of neurologic disorders. Study results from other researchers found that MS patients especially at risk for suicide are men, patients younger than 30, and patients during the first 5 years following their initial MS diagnosis.

    Dr. Feinstein reviewed findings from a study he and his associates ran on 140 consecutive patients seen at an MS clinic. The analysis showed a 29% lifetime rate of suicide intention, and a 6% rate of suicide attempts in these patients, which compared with a historical 14% intention rate in the general U.S. population and a historical 4% attempt rate reported in Canada. The study done by Dr. Feinstein identified four predictors of suicide intention in MS patients:

    • A lifetime diagnosis of major depression.

    • More severe major depression with an elevated Hospital Anxiety and Depression Scale score.

    • Living alone.

    • Alcohol abuse.

    These four factors predicted suicidal intent with 70% sensitivity, 95% specificity, and 87% overall predictive ability. One-third of the suicidal patients had received no treatment for their depression, and two-thirds of the patients in this series identified with current major depression were not on antidepressant therapy.

    Treatment for major depression in MS patients should generally follow what’s used to treat major depression in patients without MS. Only two randomized, controlled trials of antidepressant treatment have ever been reported for MS patients, and one of these studies occurred about 50 years ago, Dr. Feinstein noted. "In MS patients you need to be aware of susceptibility to side effects, but still tend to the principals from general psychiatry," he said. "The caveat for dosages is to start low and go slow. You need to be careful, especially with polypharmacy and the [potential] effect on cognition and mood."

    The disease-modifying drugs commonly used today to treat MS "are safe in patients with depression, and do not make patients suicidal. Should a patient develop depression on one of these drugs, treat the depression, which will improve compliance with the disease-modifying drugs. It is not necessary to stop the disease-modifying drugs," he said. MS patients with severe depression who remain unresponsive to antidepressants are potential candidates for electroconvulsive therapy, especially when the risk for suicide is high. But electroconvulsive therapy poses a risk for weakening the blood-brain barrier and worsening MS symptoms, so he recommended first assessing the stability of the blood-brain barrier using gadolinium-contrast MRI.

    MS patients also show a susceptibility to developing other psychiatric disorders, including pseudobulbar affect in up to 10%, bipolar affective disorder, psychosis, and an untreatable form of euphoria caused by a heavy MS-lesion load. Psychosis prevalence in MS patients aged 15-24, when most MS cases first appear, runs 11-fold higher than in the general population, said Dr. Feinstein, who also directs the neuropsychiatry program at Sunnybrook Health Sciences Centre in Toronto.

    Results from studies run by Dr. DeLuca showed that cognitive defects in MS result from slowed information processing speed and impaired learning and memory, and that these deficits can significantly impair everyday life activities. These deficits appear even in MS patients without dementia or physical disability. Risk factors for cognitive impairment include early age of onset for patients with pediatric MS or older age in patients with adult-onset MS; male sex; evidence of grey matter atrophy: evidence of low cognitive reserve: and being in the secondary progressive stage of MS.

    While disease-modifying therapies appear to have little impact on cognitive deficits, a modified approach to learning can make a substantial difference, said Dr. DeLuca, who is also professor of physical medicine and rehabilitation at New Jersey Medical School, Newark. Helpful measures include having patients "slow things down" when attempting to learn something, and asking questions to make sure they understand something correctly. MS patients also find that self-testing on new information helps strengthen their encoding. These patients "learn by slowing down and going over material again and again and testing themselves, which has a huge effect," he said in an interview. "It sounds simplistic, but this is the primary intervention."

    Dr. Feinstein said that he has received honoraria and grant support from Teva, Merck-Serono, and Bayer. Dr. DeLuca said that he has been a consultant to and received grant support from Biogen and Memen Pharmaceuticlas.

    Source: Family Practice News Copyright © 2011 International Medical News Group, LLC. (07/09/11)

    Patients with MS can benefit from group therapy sessions

    Group TherapyOffering Multiple Sclerosis patients emotional support through group therapy sessions could improve their quality of life and save the NHS almost £500 per patient, a study at The University of Nottingham has discovered.

    Researchers are now planning a larger multi-centre study into the issue to establish whether psychological therapy should be incorporated into the MS services currently provided by the NHS.

    The study, funded by the MS Society, was led by Professor Nadina Lincoln, of the University's Institute of Work, Health and Organisations. She said: "These are very encouraging findings as many people with MS have problems with depression and anxiety and there are few treatments provided in NHS clinical services to address these. It is important that the psychological effects of MS are fully recognised as they can have a devastating effect on people's lives."

    Depression and anxiety are common among sufferers of MS, a disabling neurological condition that affects around 100,000 people in the UK.

    Previous studies have suggested that depression in MS can lead to patients failing to take their medication and a reduced quality of life. National Institute for Health and Clinical Excellence (NICE) guidelines also recognise that many people with both MS and depression or anxiety would prefer not to take antidepressants and recommends that psychological therapies should be offered as an alternative.

    For the Nottingham study researchers recruited MS patients currently attending clinics run by Nottingham University Hospitals NHS Trust, as well as inviting referrals from specialist MS nurses and placing adverts in publications produced by the MS Society.

    The volunteers were asked to complete questionnaires about how MS affects their daily lives and the extent to which they felt in control.

    The patients were then randomly divided into two groups of just over 70 people. One group received all the usual care offered to MS and were put on a waiting list to receive group therapy at the end of the study.

    The other group were invited to attend a course of six two-hour sessions of group therapy attended by up to eight participants at a time. Each session was led by a research psychologist, supervised by a qualified clinical psychologist with experience of working with people with MS.

    Each session focussed on a topic, such as worry, gloom and relationships and was followed by practical exercises in strategies to cope with emotional problems and group discussion. They finished with relaxation exercises and group members were given tasks centred on practising coping strategies between sessions.

    To assess the effectiveness of the sessions, questionnaires were sent to the participants at both four and eight months later and the results of those who received treatment were compared to those on the waiting list only.

    The researchers found that those MS sufferers who attended the group sessions had fewer problems with anxiety and depression, the impact of the disease on their daily lives was reduced and their quality of life improved.

    In terms of potential savings to the NHS, the researchers have also collected information on cost, which will be submitted for a future publication. They found that costs were reduced by £470 per patient for those who attended the therapy sessions compared with usual care. It was shown to almost halve the cost of visits to the GP, falling from £11,340 at the start of the study to just £5,832 at the eight month follow up. The costs of outpatient hospital visits were also slashed from £32,592 at the beginning of the study to £21,534 at the eight-month follow-up.

    The next stage of the research will be to assess whether the group therapy approach works equally well in other centres through a larger study with the hope that the treatment could potentially be provided through NHS services for those with MS.

    Dr Susan Kohlhass from the MS Society said: "Knowing group-based sessions can reduce anxiety and depression is a strong development towards improving the quality of peoples' lives with MS. We are committed to funding work that will imminently benefit people with the condition and this is a great example. The next stage will be to find if this approach is as effective in other areas of the country."

    Source: News Medical (c) News-Medical.Net 2011 (13/06/11)

    Anxiety and depression in MS patients around diagnosis

    MS DepressionSummary: In this study the authors administered the hospital anxiety and depression scale (HADS) during diagnostic workup at baseline, and then repeated at one and six months after diagnosis disclosure. 197 patients were screened and the results suggest that anxiety was most prominent in the period surrounding MS diagnosis disclosure, particularly in women. A slight but significant reduction occurred six months after diagnosis disclosure. Depressive symptoms were less common and stable over time. In addition to sex, depressive symptoms were the only variable found to be independently associated with anxiety.

    Abstract
    OBJECTIVES:
    To prospectively identify anxiety and depressive symptoms, and their predictors, during the multiple sclerosis (MS) peridiagnostic period.

    METHODS:
    The Hospital Anxiety and Depression Scale (HADS) was administered during diagnostic workup (baseline), and one and six months after diagnosis disclosure, to SIMS-Trial participants (ISRCTN81072971).

    RESULTS:
    Of 197 screened patients, 120 (61%) were diagnosed with MS. At baseline, median HADS anxiety (HADS-A) score was 7.0 (interquartile range [IQR] 5.0-9.5), ≥8 (anxiety cut-off) in 43% (95% confidence interval [CI] 34%-52%). Median HADS depression (HADS-D) was 3.0 (IQR 1.0-5.0), ≥8 (depression cut-off) in 11% (95% CI 5%-16%). Independent predictors of anxiety were female sex (odds ratio [OR] 2.8, 95% CI 1.1-7.2) and HADS-D score (OR 20.8, 95% CI 2.5-175.5). The only predictor of depressive symptoms was HADS-A score (OR 20.0, 95% CI 2.8-260.9). Anxiety symptoms had decreased slightly but significantly (p<0.001) at six months. Depressive symptoms remained low.

    CONCLUSIONS:
    Anxiety was prominent in the period surrounding MS diagnosis disclosure, particularly in women. A slight but significant reduction occurred six months after diagnosis disclosure. Depressive symptoms were less common and stable over time. In addition to sex, depressive symptoms were the only variable independently associated with anxiety.

    Authors: Giordano A, Granella F, Lugaresi A, Martinelli V, Trojano M, Confalonieri P, Radice D, Solari A; on behalf of the SIMS-Trial group

    Source: J Neurol Sci. 2011 May 27 © 2011 Elsevier B.V. & PubMed PMID: 21621796 (02/06/11)

    Involuntary crying and laughing reported by more people with MS than expected

    Pseudobular AffectMS can impact not only physical and cognitive abilities, but also a person's emotional wellbeing. In cooperation with the research organization Infogroup/ORC and supported by an unrestricted educational grant from Avanir Pharmaceuticals, the Multiple Sclerosis Association of America (MSAA) conducted an independent, online survey of almost 20,000 of its members in the fall of 2010.

    The purpose of this survey was to better understand the extent and impact of a particularly challenging neurological condition known to occur among people living with MS: pseudobulbar affect (PBA).

    PBA is a condition that occurs in some people with certain neurological conditions, including MS, ALS (Lou Gehrig's disease), stroke, traumatic brain injury, Alzheimer's disease and others. It is characterized by exaggerated and inappropriate laughter and/or crying. During these emotional outbursts, the magnitude of the response is typically too extreme for the situation, and/or it may be inappropriate for the setting - such as laughing at a funeral or crying at a funny movie. These episodes can occur frequently, suddenly, and uncontrollably.

    Because of the crying episodes, PBA is often mistaken for depression and as a result, PBA is under-recognized. Unpredictable PBA episodes can cause embarrassment and distress leading to a significant impact on a person's employment, family relationships, social interactions, and overall quality of life.

    MSAA's goal was to survey our members to see how many people were affected by PBA and to what degree it impacted their lives. The results were surprising in both areas.

    A total of 5,229 people completed the online survey. Of these respondents, 2,504* or 48 percent reported experiencing symptoms of PBA based on their answers to a scientifically developed measurement scale.** This percentage is higher than the estimated 10 to 15 percent of the MS population that has been cited as potentially being affected by PBA.
    Our results suggest that PBA might be more widespread in the MS population than was previously thought. Additionally, the frequency of these episodes and their impact on daily life were also considerable.

    Almost 20 percent of those who reported exhibiting symptoms of PBA stated that episodes of involuntary crying and/or laughing occurred "frequently" or "often." In addition, 48 percent of those reporting PBA symptoms found their episodes to be "burdensome," almost one third of whom reported that their episodes were either "very" or "extremely" burdensome. While in most cases PBA was not considered more burdensome than their other MS symptoms, about one in four respondents indicated that PBA episodes contributed to difficulty in keeping friends or contributed to becoming housebound. Additionally, one in six indicated that PBA episodes contributed to difficulty in maintaining employment.

    For many who suffer from this unpredictable and uncontrollable condition, PBA can be debilitating, potentially interfering with many aspects of one's professional, personal, and social life. The FDA has recently approved the first treatment for PBA, Nuedexta™, which is available in capsule form.

    The results of MSAA's survey may prove valuable as this once "hidden" condition associated with MS becomes more recognized and our ability to treat PBA improves. If you are affected by the symptoms associated with PBA, you are encouraged to discuss them with your physician.

    * Of the 2,504 who reported behaviors (experiences) associated with PBA, 2,389 identified themselves as having MS and an additional 115 care partners or family members completed the survey on behalf of a person with MS.

    ** Center for Neurologic Study-Lability Scale (CNS-LS)

    Brain atrophy responsible for depression in people battling multiple sclerosis

    Depression and MSAdding to all that ails people managing their multiple sclerosis is depression ― for which MS sufferers have a lifetime risk as high as 50 percent.

    Yet despite its prevalence, the cause of this depression is not understood. It's not related to how severe one's MS is, and it can occur at any stage of the disease. That suggests it is not simply a psychological reaction that comes from dealing with the burden of a serious neurologic disorder.

    Now, in the first such study in living humans, researchers at UCLA suggest a cause, and it's not psychological, but physical: atrophy of a specific region of the hippocampus, a critical part of the brain involved in mood and memory, among other functions.

    Reporting in the early online edition of the journal Biological Psychiatry, senior study author Dr. Nancy Sicotte, a UCLA associate professor of neurology, Stefan Gold, lead author and a postdoctoral fellow in the UCLA Multiple Sclerosis Program, and colleagues used high-resolution magnetic resonance imaging to identify three key sub-regions of the hippocampus that were found to be smaller in people with MS when compared with the brains of healthy individuals.

    The researchers also found a relationship between this atrophy and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis, a complex set of interactions among three glands. The HPA axis is part of the neuroendocrine system that controls reactions to stress and regulates many physiological processes. It's thought that this dysregulation may play a role in the atrophy of the hippocampus and the development of depression.

    "Depression is one of the most common symptoms in patients with multiple sclerosis," Gold said. "It impacts cognitive function, quality of life, work performance and treatment compliance. Worst of all, it's also one of the strongest predictors of suicide."

    The researchers examined three sub-regions of the hippocampus region ― CA1, CA3 and the dentate gyrus area of the hippocampal region called CA23DG (CA stands for cornu ammonis). They imaged 29 patients with relapsing remitting multiple sclerosis and compared them with 20 healthy control subjects who did not have MS. They also measured participants' cortisol level three times a day; cortisol is a major stress hormone produced by the HPA axis that affects many tissues in the body, including the brain.

    In addition to the difference between MS patients and healthy controls, the researchers found that the multiple sclerosis patients diagnosed with depression showed a smaller CA23DG sub-region of the hippocampus, along with excessive release of cortisol from the HPA axis.

    "Interestingly, this idea of a link between excessive activity of the HPA axis and reduced brain volume in the hippocampus hasn't received a lot of attention, despite the fact that the most consistently reproduced findings in psychiatric patients with depression (but without MS) include hyperactivity of the HPA axis and smaller volumes of the hippocampus," Sicotte said.

    "So the next step is to compare MS patients with depression to psychiatric patients with depression to see how the disease progresses in each," she said.

    Other authors of the study included Kyle C. Kern, Mary-Frances O'Connor, Michael J. Montag, Aileen Kim, Ye S. Yoo and Barbara S. Giesser, all of UCLA.

    Funding was provided by the National Multiple Sclerosis Society, the National Institutes of Health, the UCLA Cousins Center for Psychoneuroimmunology, and Claire and William Vaughn.

    Source: Eureka Alert (02/07/10)

    Escitalopram provides symptom relief for patients with MS and MDD

    Depression & MSTreatment with escitalopram appears to be an effective therapy for patients who have multiple sclerosis (MS) and comorbid major depressive disorder (MDD), researchers suggested at the 2010 Annual Meeting of the American Psychiatric Association (APA).

    "Despite studies highlighting the comorbidity of multiple sclerosis and depression, it continues to be underdetected, underdiagnosed, and undertreated," stated Suzanne Hardeman, MSN, PMHNP-BC, University of South Carolina School of Medicine, Columbia, South Carolina, speaking at her poster presentation here on May 24.

    "There has not been much evidence that antidepressants are useful in treating depression in patients with multiple sclerosis. Results from this small sampled study demonstrate that escitalopram may be a viable treatment option for this population," Hardeman explained.

    Hardeman and her colleagues considered escitalopram for these patients because of the low likelihood of drug-drug interactions. The researchers, working with consent of the Institution Review Board, recruited 14 adult patients (12 women) with both MS and MDD.

    Participants were monitored for efficacy using the Hamilton Depression Rating 17-Item Scale (HAM-D17), Clinical Global Impression of Severity (CGI-S) and Improvement (CGI-I), Beck Anxiety and Depression Inventory (BAI;BDI), Expanded Disability Status Scale (EDSS), and McGill Quality of Life Scale (McQLS).

    At baseline, patients' HAM-D17 scores were 14 or greater with no history of psychotic disorder or bipolar depression. Patients had no current risk of suicide or history of substance abuse in the previous 6 months. Patients also had no history of unstable medical disorders and were not pregnant or planning pregnancy.

    Patients were administered a 10 to 20 mg flexible dose of escitalopram at bedtime in an open-label manner for 8 weeks. Patient visits occurred at baseline and at weeks 1, 2, 4, 6, and 8.

    Nine of the 14 patients completed the study. Four patients discontinued because of nausea or diarrhoea that did not resolve within 2 weeks.

    Patients responding to the treatment showed significant improvement in depressive symptoms on the HAM-D17, with scores declining from a mean of about 22 at baseline to 10 after 8 weeks (P = .000; Cognitions Questionnaire). On the BDI, mean scores declined from about 27 to about 12 after 8 weeks (P = .001). Scores from the CGI-S also were reduced greatly in patients (P = .003), and scores from the CGI-I were also significant (P = .002). McQLS scores significantly improved (P = .022), as did scaled quality of life (P = .003).

    There were no significant changes in anxiety symptoms.

    Funding for this study was provided by Forest Laboratories, Inc.

    [Presentation title: An Open-Label, 8-Week, Flexible Dose Trial of Escitalopram (Lexapro) in Comorbid Major Depression With Multiple Sclerosis. Abstract NR3-49]

    Source: Doctor's Guide Channels (c) 1995-2010 Doctor's Guide Publishing Limited (31/05/10)

    Depressive symptoms and coping in newly diagnosed patients with multiple sclerosis

    Depression and MS

    Background: Multiple sclerosis (MS) is a chronic disease with unclear etiology, unpredictable clinical course, and no cure. Patients' ability to cope with MS moderates the adaptation to the disease.

    Objectives: To compare coping in patients recently diagnosed with MS and healthy controls and to study the association between depressive symptoms and patients' coping styles.

    Methods: A sample of 86 recently diagnosed patients with definite or probable MS and 93 healthy population controls completed questionnaires assessing coping styles and depressive symptoms.

    Results: Compared with healthy controls, patients with MS used significantly less the problem focused strategies including planning, restraint coping, and seeking social support for instrumental reasons, and they used less the emotion-focused strategies seeking social support for emotional reasons, focusing on and venting of emotions, and positive reinterpretation and growth. The mean Beck Depressive symptoms Inventory scores were 10.8 and 4.7 in patients and controls, respectively. In stress situations connected to MS, depressive symptoms in these patients were related to the problem-focused strategies of restraint coping and planning, the emotion-focused strategy of focusing on and venting of emotions, and the avoidance strategies of behavioural- and mental disengagements, and denial.

    Lode K, Bru E, Klevan G, Myhr K, Nyland H, Larsen J.
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.

    Source: Pubmed PMID: 19299438 (02/04/09)

    Enhancing the mental well-being of people with multiple sclerosis

    MS Support

    A mental health nurse-led multidisciplinary team has set up a project to meet the emotional and mental health needs of patients who have multiple sclerosis

    This project provides a unique service that aims to enhance the mental and emotional well-being of people who have multiple sclerosis (MS).

    In collaboration with King's College Hospital MS service, South London and Maudsley NHS Foundation Trust, the Institute of Psychiatry and the MS Society, this service provides assessment and treatment using medication, cognitive behavioural therapy (CBT) and psychosocial interventions.

    Patients also receive education that helps to empower them to take control over their lives.

    Background

    Research suggests that mental health issues are undertreated in people with MS because of overlapping physical symptoms and that there is a high incidence of mental health problems, which is exacerbated by the uncertainty of the condition.

    However, the evidence also suggests that mental health problems in MS are treatable, with patients responding well to antidepressants/other neuroleptics and/or CBT and psychosocial interventions.

    In light of this, we felt it was necessary to provide a service to meet this need, and evaluate it after three years to ascertain whether patients do benefit from mental health nurses' input.

    As research in this area is limited, part of my work is to develop a research agenda, with a view to raising the profile of the issue within mental health and MS services.

    Aims

    People with MS can experience a variety of mental health problems, with up to 50% of them experiencing depression during their lifetime.

    There are also high rates of anxiety and other mental health problems such as psychosis, mania, pathological laughter and crying.

    Many people with MS have not received adequate care for mental health problems because of overlapping physical symptoms and difficulties in accessing services.

    Our project aims to reduce psychological distress by offering patients assessment, treatment and follow-up. We also educate MS nurses so they feel more empowered to manage mental health issues.

    The project

    The project began in March 2006 and was completed at the end of 2008. It has received over 120 referrals, indicating the service is desperately needed in the area.

    All patients complete initial assessment scales when they start treatment and rating scales at six months.

    This means we can quantify whether the service is having an impact and what patients respond well to. This will hopefully provide opportunities to make important changes and enable us to be more responsive to patient needs.

    Benefits for patients

    Patients are provided with an initial assessment within 4–8 weeks of the referral. If a patient is in crisis, I assess them within one week of referral. This is quicker than assessment by local community mental health teams and, because the service is more specific to MS, patients feel I have an understanding of their experiences.

    Care is tailored to individual patients' needs. A range of services is offered including: home visits for mental health assessment and treatment for people who are unable to attend clinic; an outpatient clinic co-managed with a neuropsychiatrist; and a CBT clinic.

    Regular teaching sessions are provided to MS nurse specialists in the south east of England.

    These nurse specialists have been asked to complete questionnaires at the beginning and end of the module to evaluate whether the teaching has changed their attitudes to mental health issues and whether they feel more confident in working with people with mental health difficulties.

    Plans

    I have developed guidelines on depression and anxiety for south-east London, and nurses in this area are using these to change their practice.

    This has been done in conjunction with their mental health training, and has led to increased confidence and positive attitudes to mental health issues. The training will also be promoted nationally with the MS Society and this will lead to further dissemination of practice.

    We plan to publish the results of the evaluation this year. We hope that publication of its benefits will lead to the project being established on a more permanent basis.

    Further studies could establish whether this model could be used in other parts of the UK.

    Find out more

    If you would like to have additional information on this project, contact [email protected] 

    Principal Author
    Sally Askey-Jones, BN, RN,is mental health nurse specialist in multiple sclerosis, Institute of Psychiatry, King's College London.

    Other authors
    Richard Gray, PhD, RN,is professor of mental health, University of East Anglia;Pauline Shaw, BSc, RN,is multiple sclerosis nurse specialist, Southwark PCT;Trudie Chalder, PhD, MSc, SRN, RN,is professor of cognitive behaviour psychotherapy;Anthony David, FRCP, FRCPsych, MSc, MD,is professor of neuropsychiatry;Kevin Gournay, CBE, PhD, FRCPsych, CPsychol, RN,is professor emeritus, all at the Institute of Psychiatry, King's College London;
    Eli Silber, MD,is neurologist, King's College Hospital, London.

    Source: Nursing Times Copyright Emap 2009 (27/02/09)

    Antidepressants Appear Ineffective in Relieving Depression in MS
    A study of multiple sclerosis (MS) patients diagnosed with major depressive disorder (MDD) and/or dysthymia shows no relation between antidepressant use and improved outcomes.

    A poster presentation here at the 21st annual meeting of the Consortium of Multiple Sclerosis Centers reported the results of a University of Washington study involving 96 MS patients enrolled in a trial investigating the value of exercise as a treatment for depression. Inclusion criteria for the study were a diagnosis of MDD and/or dysthymia based on the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV).

    Investigators became aware that some subjects in the primary study were being treated with antidepressants and some were not. This offshoot study investigated the proportion of people with MS and MDD and/or dysthymia taking antidepressants and assessed behavioural variables associated with antidepressant use.

    Celeste Hunter, from the Multiple Sclerosis Rehabilitation Research and Training Center, University of Washington, in Seattle, and an author of the poster, explained to Medscape that 1 of her colleagues noticed that although all patients in the study suffered from clinical depression, there appeared to be no discernible difference in terms of affect between patients who took antidepressants and those who did not.

    "Depression is harder to pin down in patients with MS," Ms. Hunter said. "I see the MS patients as being more emotionally reactive in a given situation than if they didn't have MS. The unpredictability factor is so important — they don't know, if they have a really bad exacerbation, whether they'll get the same function back as before."

    Almost half of the patients in this group (44%) were not taking antidepressants. Those on treatment were receiving various agents.

    Patient-Reported Antidepressant Use Treatment (%)
    None 44.0
    Fluoxetine 5.0
    Citalopram 6.0
    Bupropion 14.0
    Venlafaxine 11.0
    Sertraline 6.0
    Other 14.0


    Subjects were 85% female, 42.7% employed, and 91.7% white. Their Expanded Disability Status Scale scores were 4 or less in 52.1%, 4.5 to 6.0 in 45.8%, and 6.5 or more in 2.1%.

    The researchers compared patients taking antidepressants (n = 54) with those not taking antidepressants (n = 42) — using the Hamilton Rating Scale for Depression, the Hopkins Symptom Checklist, the Modified Fatigue Impact Scale, item 8 of the Brief Pain Inventory, and the Expanded Disability Status Scale — and found no significant difference between the outcome scores of the 2 groups on any of these scales.

    The authors concluded, "Because the study did not include people who were on antidepressants and not suffering from current MDD, our results may have been biased against finding improved outcomes associated with antidepressant use." Further studies in this area of MS treatment are needed, they added.

    Kurt Johnson, PhD, a professor in the department of rehabilitation medicine at the University of Washington, but not an author of this study, commented to Medscape that there has not been much evidence in the MS literature that antidepressants are useful in treating depression. "We found the same thing in another study with a larger group of people. A lot of people in our sample were taking antidepressants when they weren't depressed, and a lot were depressed but were not taking antidepressants."

    Higher Incidence of Depression

    Medscape also talked with Stephen Kirzinger, MD, from the Multiple Sclerosis Care Center Program, Department of Neurology, University of Louisville, in Kentucky, about this poster. "Certainly we feel that patients who have a chronic disease can develop a reactive depression, but in the MS population the incidence is much greater than what you would expect, comparing it with other chronic-disease processes," said Dr. Kirzinger. "So we feel it is a manifestation of the disease that our patients, because of their MS activity, actually have a chemical change that leads to depression."

    The antidepressants listed by patients participating in this study are serotonin reuptake inhibitors. Dr. Kirzinger noted that some preliminary data have indicated that serotonin itself has a beneficial effect on the immune system. "I think the present study flies in the face of most of our clinical experience [in which] the patients who have depression seem to respond to antidepressants. The fact that they did not see a dramatic difference between those on antidepressants and those not taking antidepressants is a little surprising."

    This study was funded by the National Rehabilitation Research and Training Center on Multiple Sclerosis from the US Department of Education, National Institute on Disability and Rehabilitation Research.

    Consortium of Multiple Sclerosis Centers 21st annual meeting: Abstract S110. (08/06/07)

    Source: MedScape Today Copyright © 1994-2007 by Medscape (06/06/07)

    Pilot program overcomes barriers to psychological care in MS patients
    The attempted suicide of a young man was the catalyst for change in the way treatment is offered to multiple sclerosis patients at Medical College of Georgia (MCG), a change that may have implications for patients beyond Augusta diagnosed with chronic illness.

    “I had seen him within the last week,” said Dr. Mary Hughes, a neurologist and director of the Augusta Multiple Sclerosis Center. “My nurse had seen him, and we had picked up on nothing. We were all just dumbfounded.”

    “When someone is diagnosed, it is a major life change,” said Dr. Sarah Shelton, a postdoctoral psychology fellow in multiple sclerosis at the center. “Patients have to learn a lot of information about their disease and go through the process of acceptance that every facet of their life could be altered significantly. It’s a huge transition.”

    Possible lifestyle changes include loss or change in job status, which can lead to a drastic financial adjustment and a loss of identity. Personal relationships are affected as the patient and family members adjust to the disease.

    The suicide rate in patients with multiple sclerosis is seven times that of any other population. Fifty percent of patients are diagnosed with depression. At the time of her patient’s suicide attempt, reports of increasingly high rates of depression, mood disorders and suicidal ideation in the MS population were being published, and Dr. Hughes went looking for solutions.

    She found Dr. Lara Stepleman, an assistant professor of psychiatry in the Department of Psychiatry and Health Behaviour, who had a strong interest in chronic medical illness care and was directing a program focused on the mental health needs of HIV patients. The two assessed needs of MS patients to determine how a psychology consult service could best help them, co-founding MS Psychology Consultation Services in 2003.

    Key to the program is the on-site availability of psychology services. Traditional mental health settings are under-utilised by MS patients for several reasons.

    Mobility plays an important role in multiple sclerosis. Multiple appointments in numerous locations can strain transportation budgets and energy levels, lessening the chance of patients receiving the service they need as symptoms of their disease fluctuate.

    The potential stigma of seeing a mental health provider decreases when psychological services are accessible during regular appointments. “Sometimes people don’t understand the many stressors that come along naturally as part of having a chronic illness, or that some of the symptoms of MS can cause psychiatric issues,” explains Dr. Stepleman. “Having it integrated as part of normal medical appointments makes it much more acceptable.”

    A patient’s emotional state has a vital connection to his physical health when treating a disease like multiple sclerosis that requires compliance and adherence to a strict medical regimen. “If they are so depressed that they are not motivated or invested enough to follow that regimen, their health is going to be directly affected,” said Dr. Shelton.

    On-site psychological services also allow inclusion of people who typically bring patients to their appointments – spouses, parents, children and other caregivers who are themselves at high risk for mental-health problems.

    Integrated medical and psychological services benefit providers as well. “Dr. Hughes helps me understand how the disease is medically affecting the patient’s emotions, cognitions or thoughts,” said Dr. Shelton, “and I help her understand some of the personality, situational and psychological factors that might be presenting. If you have separate services, the providers don’t get that complete picture, they only see half, which is a false dichotomy because the medical and psychological really work together.”

    Dr. Hughes concurs: “By keeping a psychologist involved when physicians are doing screening evaluations, it increases our effectiveness because of our different training, our different skills.”

    “This is really unique. In 95 percent of clinical services, you won’t find this level of integration,” said Dr. Stepleman. “Some programs have psychologists, but they’re not actively involved at the same time the medical treatments are being done.”

    Beginning with one clinic a week in 2004, Dr. Hughes and Dr. Stepleman committed themselves to the psychology consultation service without funding. “It was one of those ‘If you build it, they will come’ things,” said Dr. Hughes. The project received Quality of Life grants from the Multiple Sclerosis Foundation and the Christopher Reeve Foundation and a research grant from MCG’s Combined Intramural Grants Program in 2005, allowing expansion.

    The clinic’s escalating reputation for a full range of services with a high level of quality and responsiveness has fueled tremendous growth. “Patients come with an awareness of what we’re able to do,” said Dr. Hughes. The center now follows over 1,500 people with multiple sclerosis, with a psychology presence at five weekly clinics. Dr. Shelton came on board in August 2005 to manage day-to-day issues, treat patients and assist in training residents. Monthly interdisciplinary team meetings address clinical, educational and research aspects of the collaboration, and a monthly support group has begun, drawing patients and caregivers who may drive as long as two hours to attend.

    “The question hasn’t been, ‘Do we recognise this need?’” said Dr. Hughes. “It’s been, ‘How do we meet this need?’ The challenge is with mental health coverage. It’s the classic issue of limited resources in health care.”

    “That’s why getting these grants is so important,” added Dr. Shelton. “We’re able to provide psychological care at little or no charge without billing the insurance company. That allows us to provide quality comprehensive care in a way and a place the patient can receive it.”

    Since January, funding has provided for 300 depression screenings, 146 psychological consults, 108 psychotherapy/counseling sessions and 34 specialised psychological and cognitive testings. In addition to the consultation services, a two-year study based on a five-session problem-solving model for MS patients also diagnosed with clinical depression began in February to learn how to better meet patients’ needs.

    Other treatment providers are taking notice and visiting the Augusta Multiple Sclerosis Center. “People are fascinated with how we are trying to address this need,” said Dr. Hughes. “They have the same need in their clinic setting, but they’re all struggling with how to meet it. The leap from identifying the need to what’s the best way to provide those services is the gap that we’re trying to learn to fill.”

    As leaders in developing the innovative programming model, Drs. Hughes, Shelton and Stepleman are presented last week at the 22nd European Committee on the Treatment and Research of Multiple Sclerosis in Madrid, Spain, on two topics: Predicting depression and anxiety in a multiple sclerosis clinic population: the contributions of illness severity, illness management and perceived cognitive impairment; and Overcoming mental health care barriers for individuals with multiple sclerosis: innovations in psychological consultation.

    “We want to be able to spread this information so that other clinics learn from our experience,” said Dr. Hughes. “Unfortunately, we started with a crisis and worked backwards. Fortunately, the young man who had attempted suicide is now doing well. We’d have much rather been preventive. Part of what we were interested in when we developed this model was to make it applicable to various settings, and so while we were concentrating on multiple sclerosis, in the future, we’d be interested in implementing it in Parkinson’s disease or dementia or other chronic care clinics. You see enormous need and we really want to be able to pass on this information to people who can benefit from the work we’re doing here at MCG.”

    Source: MCG Science/Medical News © Medical College of Georgia All rights reserved (05/10/06)

    Neuropsychiatric Symptoms in Multiple Sclerosis
    This year, at the 16th Annual Meeting of the European Neurological Society (ENS), Sara Pires-Baranta, PsyD, a neuropsychologist at the Hospital do Espirito Santo in Evora, Portugal presented surprising data, which collected from studying neuropsychiatric symptoms in her multiple sclerosis patients from 2001 to 2005.

    Her data contradicted the widespread belief that depression is the most common neuropsychiatric symptom in MS.

    In her study, sleep disorders occurred in 82% of the patients, significant obsessive-compulsive symptoms in 75%, and some form of eating disorder in 67%. Depression was seen in 61%, which is higher than the estimated 40%.

    Source: About ©2006 About, Inc. (19/07/06)

    Related Items
    Bacteria
    Biomarkers And MicroRNA
    Blood Tests And MS
    Botox
    Brain Inflammation
    Brain Iron Deposits
    Cancer And MS
    Chronic Cerebrospinal Venous Insufficiency (CCSVI)
    Cognition and Cognitive Issues
    CRMP-2
    Diet And MS
    Drugs
    Endo-parasites & 'Helpful' Organisms
    Environmental Factors And MS
    Ethnic Groups and MS
    Exercise And MS
    Genetics and MS
    Hormones And MS
    Immune Cells And MS
    Kallikrein 6
    Lightning Process® And Multiple Sclerosis
    Lipids And MS
    Lymphoid Tissue Inducer (LTi) Cells
    Medical Imaging
    MS Stem Cell Research & Treatment
    MS Symptoms
    Myelin
    Nerve And Brain Cells
    Neurosteroids
    Osteoporosis And MS
    Paediatric MS
    Pain
    Potential Viral Causes Of MS
    Pregnancy And MS
    Quality Of Life
    Stress And MS
    Technology And MS
    The Blood Brain Barrier
    Types Of MS
    Vaccinations & MS
    Vitamin D


    Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.